State Street Corp Cogent Biosciences, Inc. Transaction History
State Street Corp
- $2.59 Trillion
- Q2 2025
A detailed history of State Street Corp transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, State Street Corp holds 3,371,912 shares of COGT stock, worth $47.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,371,912
Previous 4,116,796
18.09%
Holding current value
$47.6 Million
Previous $24.7 Million
1.82%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding COGT
# of Institutions
203Shares Held
117MCall Options Held
2.84MPut Options Held
828K-
Paradigm Biocapital Advisors LP New York, NY10.4MShares$146 Million3.47% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.49MShares$120 Million7.28% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$103 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$98.4 Million10.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.52MShares$92.2 Million0.0% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $929M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...